Chemokine Therapeutics Announces Preliminary Results of CTCE-9908 Phase IB/II Clinical Trial in Late Stage Cancer Patients

14-Mar-2007

Chemokine Therapeutics Corp. announced positive preliminary data and the successful completion of the dose-escalation portion of its Phase Ib/II clinical trial for CTCE-9908, the Company's anti-cancer drug candidate. No dose limiting toxicities were observed in any of the cancer patients and two out of three patients with ovarian cancer responded positively and exhibited stable disease.

Chemokine Therapeutics will now proceed with the remaining portion of the clinical trial in which up to twenty additional patients will be treated at 5mg/kg/day. The Company expects to enroll the remainder of the patients and complete the current trial by the end of Q3 2007. The Company has also accelerated its efforts to initiate a large Phase II program in the U.S. by the end of 2007. Accordingly, a pre-IND meeting has been scheduled with the FDA to discuss the Company's future clinical trial program.

CTCE-9908 is a peptide analog of the Chemokine SDF-1, and an antagonist of its receptor, CXCR4. According to the company, SDF-1 is the only known naturally occurring chemokine that binds to CXCR4, which is present on many cancer cells. This binding process is believed to be critical in angiogenesis and in the metastasis (or spread) of cancer cells to distant locations in the body, where they form new tumors. Approximately 90% of cancer deaths are due to metastasis. We believe that CTCE-9908 interferes with the metastatic process of cancers by both preventing them to spread and blocking the blood supply to the cancer cells.

https://www.bionity.com/en/news/62734/chemokine-therapeutics-announces-preliminary-results-of-ctce-9908-phase-ib-ii-clinical-trial-in-late-stage-cancer-patients.html